AZD5363 (Capivasertib)
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for AZD5363 (Capivasertib), covering 2021-08-10 to 2025-07-22. Get the full timeline:
Most recent: Clinical Trial Update: Phase I Study of AZD5363 + Olaparib + Durvalumab in Patients With Advanced or Metastatic Solid Tumor Malignancies [Phase 1]